209-283-7 | Sigma-Aldrich

Examination of Non-Specifically Bound Proteins and Peptides Following Depletion of Twenty High Abundance Proteins from Human Plasma

a chain precursor 282 5 IPI00298497 Fibrinogen b chain precursor 267 5 199 5 107 2 225 7 61 1 240 6 342 9 209 6 352 8 IPI00021891 Fibrinogen gamma chain precursor 51 1 68 3 70

Product Information Sheet - 11539426001

Mol. Cel. Biol. 2, 1044. 4 Borras, T., et al., (1988) Dev. Biol. 127, 209. 5 Lederberg, J., (1950) 6 Bacteriol. Proc. 60, 381. 7 Miller,J. H., (1972) Experiments in Molecular Genetics, Cold Spring Harbor

Perfection in every dimension - Inorganic Reagents catalog

form 107150 283 Paraffin 46 – 48, in block form 107151 283 Paraffin 51 – 53, in pastille form Ph Eur, BP, NF 107157 283 Paraffin 52 – 54, in pastille form Ph Eur, BP, NF 107300

Antibody SourceBook, Sixth Edition, DIST version

Xenopus ST1110 100 µl €283 PhosphoDetect™ Anti-MKK7 (pSer271, Thr275) Rabbit pAb IB human ST107� 50 µl €199 Anti-MKK7 Mouse mAb (3F5) ELISA, IB human ST1031 100 µg €397 Anti-MKP-7 (2-1�) Goat pAb IB

Calbiochem Biologics 33.2

cell types and should be determined empirically by the investigator. Cat. No. QIA76 100 Tests €283 Ref.: Luther, E ., and Kamenstsky, L .A . 1996 . Cytometry 23, 272; Frey . T ., et al . 1995 . Cytometry

Chrombook (WEB-Version)

1.50482.0001 283 1.50483.0001 283 1.50484.0001 283 1.50487.0001 283 1.50489.0001 283 1.50490.0001 283 1.50491.0001 283 1.50492.0001 283 1.50493.0001 283 1.50494.0001 283 1.50495.0001

MAPK: Antibodies, Proteins, Kits, siRNA and Reagents

100 µg 04-282 Anti-phospho-EGFR (Thr669) 100 µg 04-281 Anti-phospho-EGFR (Tyr845) 100 µg 04-283 Anti-phospho-EGFR (Tyr1045) 100 µg 04-284 Anti-phospho-EGFR (Ser1047) 100 µg 04-280 Anti-phospho-EGFR

XP725 Antibody List Lot 129K4831

PTK2B P NP_004094.3 y n/d n/d 273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1 y y n/d 283 FOXC2 F1054 2303 FOXC2 P NP_005242.1 y y n/d 279 FKHR (FOXO1a) F6928 2308 FOXO1 M NP_002006.2 y n

XP725 Antibody List Lot 129K4830

PTK2B P NP_004094.3 y n/d n/d 273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1 y y n/d 283 FOXC2 F1054 2303 FOXC2 P NP_005242.1 y y n/d 279 FKHR (FOXO1a) F6928 2308 FOXO1 M NP_002006.2 y n

XP725 Antibody List Lot 089K4791

PTK2B P NP_004094.3 y n/d n/d 273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1 y y n/d 283 FOXC2 F1054 2303 FOXC2 P NP_005242.1 y y n/d 279 FKHR (FOXO1a) F6928 2308 FOXO1 M NP_002006.2 y n

Tools and Tips for Analyzing Apoptosis: A Kit Selection Guide

Ac-AAVALLPAVLLALLAP-YVAD-CHO Yes Yes 1, 4 1 mg €204 Caspase-1 Inhibitor II 400012 Ac-YVAD-CMKb Yes No 1, 4 5 mg €283 Caspase-1 Inhibitor II, Biotin Conjugate 400022 Biotin-YVAD-CMKb — No 1, 4 5 mg €365 Caspase

Hallmarks of Cancer - Solutions for life science research

Chemiluminescence Detection 17-360 Ras Activation Assay Kit 17-218 Rac1 Activation Assay Kit 17-283 Rho Activation Assay Kit 17-294 Rac1/Cdc42 Activation Assay Kit 17-441 Rac1/cdc42 Activation

Bioreactor Systems for Bone Tissue Engineering

. Adaptation of connexin 43-hemi- channel prostaglandin release to mechanical loading. J Biol Chem 283, 26374, 2008. 125. Sikavitsas, V.I., Temenoff, J.S., and Mikos, A.G. Biomater- ials and bone mechanotransduction

XP725 Worksheet for Lot Number 071M4826

pThr41 C8616 279 2 2 5 7 b Catenin pSer33pSer37 C4231 280 2 2 5 8 bCatenin pSer33pSer37 C4231 281 2 2 6 1 phospho-b-Catenin pSer45 C5615 282 2 2 6 2 phospho-b-Catenin pSer45 C5615 283 2 2 6 3 bCatenin pSer33

Calbiochem Biologics 32.4

interacting with their BIR domain. Purity: ≥ 85% by SDS-PAGE. M.W. 72,300 Cat. No. 539661 50 mg € 283 Ref.: Herrera, B ., et al . FEBS Lett. 520, 93; Deveraux, Q .L . and Reed, J .C . 1999

Stem Cell and Specialty Cell Culture Product Guide

299 Fax: 0180 5 045644 Email: technischerservice@millipore.com hungary Phone: 01 209 3232 Fax: 01 209 0295 Email: gyongyi_harta@millipore.com ireland Phone: 01605 8401 Fax: 0870 900

List of Antibodies

n/d 205 Cytokeratin peptide 7 C6417 M y n/d n/d 206 Cytokeratin 8.12 C7034 M y n/d n/d 207 Cytokeratin 8.13 C6909 M y n/d n/d 208 Cytokeratin peptide 13 C0791 M y n/d n/d 209 Cytokeratin Peptide 17 C9179

TLC Application compilation

p-methylaminophenol 1g in 500ml water

Cytoskeletal Signaling Antibodies, Reagents and Kits

clone D2D6 06-730 anti-Rho-GDI 05-219 anit-Vav 07-192 Anti-Vav 07-464 anti-Vav3 17-283 Rac Activation Assay 17-369 Rac2 Activation Assay 14-325 Rac/Cdc42 Assay Reagent (PAK1, Agarose

XP725 Antibody List

y n/d n/d 282 FLIPγ/δ, C-Terminal F9925 12633, 8837 Cflar,CFLAR NP_997536.1,NP_003870.3 P y y n/d 283 FOXC2 F1054 14234, 2303 Foxc2,FOXC2 NP_038547.2,NP_005242.1 P y y n/d 284 FOXP2 F6304 93986, 114142

XP725 Antibody List 013M4793

y n/d n/d 282 FLIPγ/δ, C-Terminal F9925 12633, 8837 Cflar,CFLAR NP_997536.1,NP_003870.3 P y y n/d 283 FOXC2 F1054 14234, 2303 Foxc2,FOXC2 NP_038547.2,NP_005242.1 P y y n/d 284 FOXP2 F6304 93986, 114142

Inhibitor Sourcebook 3rd Edition

................................ 209 Phosphodiesterase Inhibitors ................................................................................................... 209 Poly(ADP-ribose) Polymerase (PARP

Halal Certificate

Product Certificate # 282. 4-METHYL-1-PHENYL-2-PENTANONE 95%, FG W274003 B60061 HC-23SIH956 283. 4-METHYL-2-PHENYL-2-PENTENAL, MIXTURE OF CIS AND TRANS 88%, STABILIZED W320005 B45864 HC-23SIBK61

Halal Certificate

Product Certificate # 282. 4-METHYL-1-PHENYL-2-PENTANONE 95%, FG W274003 B60061 HC-22SIDV77 283. 4-METHYL-2-PHENYL-2-PENTENAL, MIXTURE OF CIS AND TRANS 88%, STABILIZED W320005 B45864 HC-22SIA982

Perfección en todas sus dimensiones. Catálogo de reactivos inorgánicos

107300 283 Parafina 56 - 58, en forma de pastilla Farm. Eur, BP, NF 107337 283 Parafina 57 - 60, en forma de pastilla Farm. Eur, BP, NF 107158 283 Parafina líquida Reac. Farm. Eur 107162 283 Parafina

BRAND Katalog EN

4720 00 - 4722 00 209 4725 00 210 4726 00 - 4727 00 209 4728 00 210 4731 00 209 4735 00 - 4743 05 211 4744 00 - 4744 10 210 4747

Katalog neoLab

. . .177 7-3015 to 7-3018 . . . . . . . . .177 7-3040 to 7-3043 . . . . . . . . .456 7-3047 . . . . . . . . .